At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
CJM112 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Subject and Investigator Blinded, Placebo-controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
In Brief
A Phase 2 clinical trial evaluating CJM112 and Placebo for Acne Vulgaris. Completed, enrolled 52 participants across 10 sites in 3 countries.
Detailed Summary
The study was designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship were to be explored.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesGermany, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionAug 2018
TodayJul 2026
First PostedDec 20, 2016
Enrollment StartDec 22, 2016
Primary CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.5 years ago
Interventions
CJM112biological
Placeboother